Advanced

Similarity of uterine mucosa changes in patients treated by Raloxifen and Tamoxifen

Willen, R; Willlen, H and Lindahl, Bengt LU (2002) In Anticancer Research 22(2B). p.1121-1125
Abstract
Background: Selective estrogen receptor modulators (SERMS) like Tamoxifen and Raloxifen are used for menopausal symptoms, prevention of cardio-vascular diseases, osteoporosis and mammary carcinoma. Tamoxifen acts as an estrogen inhibitor on the mammary gland, but stimulates postmenopausal uterine mucosa in about 25% of cases while decreasing the risk of osteoporosis. Materials, Methods and Results: In three menopausal women, 56, 79 and 62 years of age, we found uterine mucosal changes similar to what is found in Tamoxifen-treated patients. Using light microscopy and immuno-histopathological techniques, partly cystic mucosa with both atrophic and proliferating glands was found. Strong stromal proliferation was also seen with the typical... (More)
Background: Selective estrogen receptor modulators (SERMS) like Tamoxifen and Raloxifen are used for menopausal symptoms, prevention of cardio-vascular diseases, osteoporosis and mammary carcinoma. Tamoxifen acts as an estrogen inhibitor on the mammary gland, but stimulates postmenopausal uterine mucosa in about 25% of cases while decreasing the risk of osteoporosis. Materials, Methods and Results: In three menopausal women, 56, 79 and 62 years of age, we found uterine mucosal changes similar to what is found in Tamoxifen-treated patients. Using light microscopy and immuno-histopathological techniques, partly cystic mucosa with both atrophic and proliferating glands was found. Strong stromal proliferation was also seen with the typical sharp-edged form of stromal cells and mitoses. A strong ostrogen and progesterone reaction was revealed with immuno-histopathological techniques in both gland and stromal parts. Conclusion: Taking into account the variable amount of different estrogen-receptor types in the uterine mucosa, we can not in the long run expect that no patient will react with estrogen-stimulation features on SERMs like Raloxifen. Further studies and thorough observations are needed to elucidate the true frequency of Raloxifen impact on the uterine mucosa. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
histopathology, uterine mucosa, polyps, Raloxifen
in
Anticancer Research
volume
22
issue
2B
pages
1121 - 1125
publisher
International Institute of Cancer Research
external identifiers
  • wos:000177246300014
  • scopus:0036327135
ISSN
1791-7530
language
English
LU publication?
yes
id
f986d2b7-9dcf-47c0-9b63-628c31e03a1b (old id 332165)
date added to LUP
2007-11-16 12:08:38
date last changed
2017-01-01 04:29:58
@article{f986d2b7-9dcf-47c0-9b63-628c31e03a1b,
  abstract     = {Background: Selective estrogen receptor modulators (SERMS) like Tamoxifen and Raloxifen are used for menopausal symptoms, prevention of cardio-vascular diseases, osteoporosis and mammary carcinoma. Tamoxifen acts as an estrogen inhibitor on the mammary gland, but stimulates postmenopausal uterine mucosa in about 25% of cases while decreasing the risk of osteoporosis. Materials, Methods and Results: In three menopausal women, 56, 79 and 62 years of age, we found uterine mucosal changes similar to what is found in Tamoxifen-treated patients. Using light microscopy and immuno-histopathological techniques, partly cystic mucosa with both atrophic and proliferating glands was found. Strong stromal proliferation was also seen with the typical sharp-edged form of stromal cells and mitoses. A strong ostrogen and progesterone reaction was revealed with immuno-histopathological techniques in both gland and stromal parts. Conclusion: Taking into account the variable amount of different estrogen-receptor types in the uterine mucosa, we can not in the long run expect that no patient will react with estrogen-stimulation features on SERMs like Raloxifen. Further studies and thorough observations are needed to elucidate the true frequency of Raloxifen impact on the uterine mucosa.},
  author       = {Willen, R and Willlen, H and Lindahl, Bengt},
  issn         = {1791-7530},
  keyword      = {histopathology,uterine mucosa,polyps,Raloxifen},
  language     = {eng},
  number       = {2B},
  pages        = {1121--1125},
  publisher    = {International Institute of Cancer Research},
  series       = {Anticancer Research},
  title        = {Similarity of uterine mucosa changes in patients treated by Raloxifen and Tamoxifen},
  volume       = {22},
  year         = {2002},
}